Clinical Trials Browser

Interventional × elotuzumab × 30 days × Clear all

NCT06158841 2026-03-13

CERVINO

Phase 3 Recruiting

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

Phase 3 Recruiting

Multiple Myeloma

NCT03361306 2026-03-06

LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

Phase 2 Completed

15 enrolled 26 charts

Multiple Myeloma, Recurrence